
Results
17
17 companies
Axsome Therapeutics
Market Cap: US$12.9b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$250.50
7D
-1.8%
1Y
148.8%
Ionis Pharmaceuticals
Market Cap: US$12.2b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$74.12
7D
0.2%
1Y
96.8%
Elanco Animal Health
Market Cap: US$12.1b
An animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
ELAN
US$24.22
7D
-0.3%
1Y
81.4%
Waters
Market Cap: US$34.9b
Provides analytical workflow solutions in Asia, the Americas, and Europe.
WAT
US$355.44
7D
-0.6%
1Y
3.7%
Natera
Market Cap: US$33.1b
A diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
NTRA
US$231.41
7D
9.1%
1Y
34.7%
Insmed
Market Cap: US$20.8b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$95.80
7D
-1.7%
1Y
-9.1%
BioMarin Pharmaceutical
Market Cap: US$10.6b
A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
BMRN
US$54.69
7D
-1.7%
1Y
1.1%
Madrigal Pharmaceuticals
Market Cap: US$11.7b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$505.75
7D
1.2%
1Y
78.7%
Viatris
Market Cap: US$17.9b
Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
VTRS
US$15.37
7D
-6.7%
1Y
73.3%
Alnylam Pharmaceuticals
Market Cap: US$37.1b
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
ALNY
US$278.09
7D
-3.4%
1Y
-11.2%
Jazz Pharmaceuticals
Market Cap: US$14.1b
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
JAZZ
US$224.66
7D
-2.6%
1Y
110.4%
BeOne Medicines
Market Cap: US$30.0b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$270.15
7D
2.1%
1Y
9.3%
Royalty Pharma
Market Cap: US$30.5b
Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
RPRX
US$52.96
7D
-2.4%
1Y
49.6%
Neurocrine Biosciences
Market Cap: US$15.9b
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
NBIX
US$158.29
7D
-0.9%
1Y
25.1%
Merck
Market Cap: US$281.2b
Operates as a healthcare company worldwide.
MRK
US$113.87
7D
-0.9%
1Y
42.1%
Krystal Biotech
Market Cap: US$10.3b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
KRYS
US$348.06
7D
7.2%
1Y
152.4%
Gilead Sciences
Market Cap: US$153.7b
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
GILD
US$123.76
7D
-0.4%
1Y
16.5%